Fact Source: Financial Supervisory Service DART / 2025-01-22
Disclosure Type: Tentative Operating Performance based on Consolidated Financial Statements (Fair Disclosure)
💡 3-Second Summary
SAMSUNG BIOLOGICS recorded a strong performance for the full year of 2024, posting approximately KRW 4.55T in consolidated revenue and KRW 1.32T in operating profit, translating to a year-over-year expansion of 23.08% and 18.53%, respectively.
📊 1. [Key Disclosure Content & Major Figures Summary]
- Q4 2024 Consolidated Tentative Performance (Unit: KRW):
- Revenue: KRW 1,256,439,000,000 (KRW 1.256T)
- Compared to Previous Quarter (Q3 2024): +5.84%
- Compared to Same Period Last Year (Q4 2023): +17.04%
- Operating Profit: KRW 325,664,000,000 (KRW 325.7B)
- Compared to Previous Quarter (Q3 2024): -3.81%
- Compared to Same Period Last Year (Q4 2023): -6.94%
- Net Income: KRW 321,494,000,000 (KRW 321.5B)
- Compared to Previous Quarter (Q3 2024): +21.56%
- Revenue: KRW 1,256,439,000,000 (KRW 1.256T)
- Full-Year 2024 Cumulative Consolidated Performance (Unit: KRW):
- Revenue: KRW 4,547,322,000,000 (KRW 4.547T, +23.08% increase compared to previous year’s cumulative total)
- Operating Profit: KRW 1,320,052,000,000 (KRW 1.320T, +18.53% increase compared to previous year’s cumulative total)
- Net Income (Controlling Interest Same): KRW 1,083,316,000,000 (KRW 1.083T, +26.31% increase compared to previous year’s cumulative total)
- Note: The disclosure filing does not explain the specific causes behind the performance fluctuations, such as the full-year top-line expansion or the Q4 sequential operating profit decline. These figures are tentative and have not yet been audited by an external auditor, meaning they remain subject to change.
📈 2. [Expert Insight: What This Disclosure Means for Investors]
This fair disclosure provides the definitive tentative framework for SAMSUNG BIOLOGICS’ entire FY2024 operating results, offering critical baseline indicators regarding the firm’s annualized structural growth.
The primary fundamental takeaway is the robust expansion of the company’s annual operating scale. Surpassing the KRW 4.5T milestone in cumulative revenue and generating over KRW 1.32T in annualized operating yields documents that the core commercial model maintains heavy fundamental strength. Data validation checks out perfectly, with headline revenue comfortably exceeding the operating profit lines across all segments.
However, monitoring the standalone Q4 metrics reveals a minor divergence: while Q4 revenue sustained upward momentum by expanding 5.84% sequentially, standalone Q4 operating profit contracted by 3.81% quarter-over-quarter and 6.94% year-over-year. Because the filing does not detail the qualitative drivers behind this specific margin compression, investors should avoid definitive assumptions regarding near-term profitability trends. Instead, market participants should cross-reference these preliminary metrics with the detailed IR briefing materials to be published on the corporate site to differentiate between routine year-end accounting adjustments and structural operational variables.
📝 Editor’s Comment (by K-STOCK Editor)
SAMSUNG BIOLOGICS has officially entered the KRW 4.5T annual revenue bracket, showcasing the massive operating leverage typical of a premier tier-one large cap. Achieving consecutive annual top-line growth of 23% and operating profit expansion of 18% reinforces the stability of their global CDMO backlog conversion.
Nevertheless, institutional analysts will likely scrutinize the minor sequential softening in standalone Q4 operating yields. The top line expanded while operating margins contracted slightly, signaling a short-term increase in localized expenditure lines, a detail left unaddressed in this initial text. Given that these metrics are tentative pending a final audit, this variance could stem from typical year-end accounting adjustments. Rather than reacting to short-term quarterly fluctuations, global market participants should rely on upcoming IR materials to assess the underlying structural health of the backlog before adjusting long-term valuations.
📢 Disclaimer and Source Information
Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
